MEC Practice Academy 11.19
|Articles|July 18, 2008

New Drug Marketing Guidelines Limit Freebies

Sorry, doctorsâ€"no more coffee mugs, no more pens, no more note pads, no more free restaurant meals. That's the gist of the new marketing code of ethics put out by PhRMA, the brand-name drug industry's trade group, which also suggests that drug companies cap speaking and consultant fees to doctors. Under the code, drug companies must also require doctors who are paid speakers or consultants to reveal those ties if they sit on committees that compile drug formularies or treatment guidelines.

Sorry, doctors—no more coffee mugs, no more pens, no more note pads, no more free restaurant meals. That’s the gist of the new marketing code of ethics put out by PhRMA, the brand-name drug industry’s trade group, which also suggests that drug companies cap speaking and consultant fees to doctors. Under the code, drug companies must also require doctors who are paid speakers or consultants to reveal those ties if they sit on committees that compile drug formularies or treatment guidelines.

The move is in response to increasing pressure from lawmakers and consumer groups, which see the gifts and payments as an attempt to influence doctors’ prescribing habits. The ethics code was unanimously backed by PhRMA’s member companies, and drug giants like Eli Lilly, Johnson & Johnson, and Pfizer have publicly supported it.

Critics charge, however, that the new code should have banned fees for speakers and consultants outright. They also point out that the code still allows in-office catered meals, as well as funding for continuing medical education (CME) programs. In addition, some consumer groups maintain that, as a trade group, PhRMA has no enforcement power. In response, a PhRMA spokesperson points out that the code requires drug company CEOs to certify annually that they have policies and procedures in place to comply with code guidelines.


Related to this article

Stroke survivors get a first-of-its-kind anticoagulant; Queens day care director admits $127M Medicare, Medicaid fraud; ovarian cancer may leave an early mark in the blood — Morning Medical Update © kwanchaichaiudom - stock.adobe.com
The top news stories in medicine today: The FDA approves the first factor XIa inhibitor to reduce the risk of a repeat stroke; a Queens adult day care program director pleads guilty in a $127 million Medicare and Medicaid fraud scheme; researchers tie a blood RNA signal to the precancerous stage of ovarian cancer.